Pharmacotherapy for childhood obesity: present and future prospects

Pediatric obesity is a serious medical condition associated with significant comorbidities during childhood and adulthood. Lifestyle modifications are essential for treating children with obesity, yet many have insufficient response to improve health with behavioral approaches alone. This review summarizes the relatively sparse data on pharmacotherapy for pediatric obesity and presents information on obesity medications in development. Most previously studied medications demonstrated, at best, modest effects on body weight and obesity-related conditions. It is to be hoped that the future will bring new drugs targeting specific obesity phenotypes that will allow clinicians to use etiology-specific, and therefore more effective, anti-obesity therapies.

[1]  Ahmad Al Rousan Middle east review , 2007 .

[2]  Bacon Ge,et al.  A clinical trial of fenfluramine in obese children. , 1967 .

[3]  D. Chlebna-Sokół,et al.  [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)]. , 1981, Przeglad lekarski.

[4]  B. Barton,et al.  A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. , 2006, The American journal of psychiatry.

[5]  C. Weyer,et al.  Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. , 2003, Metabolism: clinical and experimental.

[6]  Paul Webb,et al.  Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight , 2004, Trends in Endocrinology & Metabolism.

[7]  Dong-Chul Seo,et al.  A meta-analysis of obesity interventions among U.S. minority children. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[8]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[9]  S. Inzucchi,et al.  Metformin: new understandings, new uses. , 2003, Drugs.

[10]  K. Westerterp,et al.  The effect of sibutramine on energy expenditure and body composition in obese adolescents. , 2007, Journal of Clinical Endocrinology and Metabolism.

[11]  S. Gahagan,et al.  Overweight and Obesity , 2011 .

[12]  F. de Zegher,et al.  Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. , 2004, The Journal of clinical endocrinology and metabolism.

[13]  Darrell M. Wilson Analysis of metformin treatment for adolescent obesity at 48 rather than 24 weeks after treatment cessation. , 2010 .

[14]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[15]  J. McNeil,et al.  Pharmacotherapies for Obesity: Past, Current, and Future Therapies , 2010, Journal of obesity.

[16]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[17]  L. Baur,et al.  Adiposity and body mass indices in children: Benn's index and other weight for height indices as measures of relative adiposity. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[18]  K. Westerterp,et al.  Short-term effects of growth hormone on body composition as a predictor of growth. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  A. Astrup Thermogenic drugs as a strategy for treatment of obesity , 2000, Endocrine.

[20]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[21]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[22]  M. Trautmann,et al.  Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years , 2011, BMC endocrine disorders.

[23]  D. Giugliano,et al.  Pharmacokinetic-Pharmacodynamic Relationships of Acarbose , 1996, Clinical pharmacokinetics.

[24]  K. Rice,et al.  Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.

[25]  A. Grüters,et al.  Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. , 2010, European journal of endocrinology.

[26]  M. Schwartz,et al.  Elevated plasma ghrelin levels in Prader–Willi syndrome , 2002, Nature Medicine.

[27]  R. Krauss,et al.  Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins , 2008, Proceedings of the National Academy of Sciences.

[28]  Mary T. Brinkoetter,et al.  Leptin is an effective treatment for hypothalamic amenorrhea , 2011, Proceedings of the National Academy of Sciences.

[29]  K. Gadde,et al.  Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. , 2002, Obesity research.

[30]  V. Hubbard,et al.  Efficacy of Orlistat as an Adjunct to Behavioral Treatment in Overweight African American and Caucasian Adolescents with Obesity-related Co-morbid Conditions , 2004, Journal of pediatric endocrinology & metabolism : JPEM.

[31]  H. Chase,et al.  A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes , 2009, Pediatrics.

[32]  C. Mantzoros,et al.  Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance , 2011, Diabetes.

[33]  R. Baldessarini,et al.  Open trial of bupropion SR in adolescent major depression. , 2003, Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc.

[34]  C. Winick,et al.  Three controlled trials of weight loss with phenylpropanolamine. , 1982, International journal of obesity.

[35]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[36]  S. Heymsfield,et al.  Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.

[37]  Arya M. Sharma,et al.  Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. , 2010, The New England journal of medicine.

[38]  M. Cowley,et al.  Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice , 2007, Neuropsychopharmacology.

[39]  M. Schwartz Brain Pathways Controlling Food Intake and Body Weight , 2001, Experimental biology and medicine.

[40]  D. Stewart,et al.  Tenuate dospan as an appetitie suppressant in the treatment of obese children. , 1970, Applied therapeutics.

[41]  A. Halpern,et al.  The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. , 1996, Obesity research.

[42]  D. Boulton,et al.  Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects , 2009, Clinical pharmacology and therapeutics.

[43]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[44]  D. Lackland,et al.  Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Meta , 2005, The American journal of the medical sciences.

[45]  S. Dakhli,et al.  [Obesity in children]. , 2000, La Tunisie medicale.

[46]  Zhengyan Zhao,et al.  Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention , 2007, International Journal of Obesity.

[47]  L. Epstein,et al.  Growth in obese children treated for obesity. , 1990, American journal of diseases of children.

[48]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.

[49]  P. Tønnesen,et al.  The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain * , 1996, Clinical pharmacology and therapeutics.

[50]  W. Poston,et al.  Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials , 2002, International Journal of Obesity.

[51]  J. Rosenstock,et al.  Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes , 2010, Diabetes Care.

[52]  T. Cole,et al.  What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? , 2005, European Journal of Clinical Nutrition.

[53]  Leonard H Epstein,et al.  Family-based obesity treatment, then and now: twenty-five years of pediatric obesity treatment. , 2007, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[54]  S. O’Rahilly,et al.  Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[55]  B. Zinman,et al.  Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) , 2010 .

[56]  A. Astrup,et al.  The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men , 2010, International Journal of Obesity.

[57]  S. Del Prato,et al.  [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. , 2013, Deutsche medizinische Wochenschrift.

[58]  Darrell M. Wilson,et al.  Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. , 2010, Archives of pediatrics & adolescent medicine.

[59]  T. Sørensen,et al.  Childhood body-mass index and the risk of coronary heart disease in adulthood. , 2008, The New England journal of medicine.

[60]  M. Krotkiewski Thyroid hormones and treatment of obesity , 2000, International Journal of Obesity.

[61]  T. Pischon,et al.  Recent developments in the treatment of obesity-related hypertension , 2002, Current opinion in nephrology and hypertension.

[62]  U. Ekelund,et al.  Genetic Susceptibility to Obesity and Related Traits in Childhood and Adolescence , 2010, Diabetes.

[63]  M. Forrester Pattern of orlistat exposures in children aged 5 years or less. , 2009, The Journal of emergency medicine.

[64]  K. Gadde,et al.  Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. , 2007, The Journal of clinical psychiatry.

[65]  D. Vukovic [Obesity in childhood]. , 1972, Srpski Arhiv za Celokupno Lekarstvo.

[66]  D. Molnár,et al.  Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents , 2000, International Journal of Obesity.

[67]  A. Haqq,et al.  Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[68]  Corby K. Martin,et al.  Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. , 2011, Journal of Clinical Endocrinology and Metabolism.

[69]  R. Canitano Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders , 2005, Brain and Development.

[70]  J. Lorber Obesity in childhood. A controlled trial of anorectic drugs. , 1966, Archives of disease in childhood.

[71]  P. Mirmiran,et al.  Childhood obesity in the Middle East: a review. , 2010, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[72]  S. Toubro,et al.  Effects of the two β3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects , 2000, International Journal of Obesity.

[73]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[74]  C. Weyer,et al.  Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats , 2008, International Journal of Obesity.

[75]  K. Flegal,et al.  Prevalence of high body mass index in US children and adolescents, 2007-2008. , 2010, JAMA.

[76]  Robin Christensen,et al.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.

[77]  M. Boldrin,et al.  Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. , 2005, JAMA.

[78]  J. Spranger [Phentermine resinate in obesity. Clinical trial of Mirapront in adipose children]. , 1965, Münchener medizinische Wochenschrift.

[79]  Christian Weyer,et al.  Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.

[80]  J. Rutledge,et al.  Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial , 2006, International Journal of Obesity.

[81]  M. Lesch,et al.  Sudden death associated with thyroid hormone abuse. , 1981, The American journal of medicine.

[82]  F. Karlsson,et al.  Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. , 2003 .

[83]  T. Lutz,et al.  Brainstem mechanisms of amylin-induced anorexia , 2010, Physiology & Behavior.

[84]  A. Hokken-Koelega,et al.  Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. , 2006, The Journal of clinical endocrinology and metabolism.

[85]  K. Gadde,et al.  Rational Design of a Combination Medication for the Treatment of Obesity , 2009, Obesity.

[86]  G. Colditz,et al.  Adiposity in adolescents: change in actual BMI works better than change in BMI z score for longitudinal studies. , 2007, Annals of epidemiology.

[87]  P. O'Neil,et al.  Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.

[88]  A. Berkenstam,et al.  The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans , 2008, Proceedings of the National Academy of Sciences.

[89]  S. Garattini,et al.  Neurochemical mechanism of action of anorectic drugs. , 1993, Pharmacology & toxicology.

[90]  M. Worsham,et al.  Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[91]  A. Powell Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .

[92]  Masahiko Watanabe,et al.  Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese Rats , 2008, Diabetes.

[93]  B. Beech,et al.  Attrition in paediatric weight management: a review of the literature and new directions , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[94]  H. Chase,et al.  Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. , 2009, The Journal of pediatrics.

[95]  G. Lowrey,et al.  A clinical trial of fenfluramine in obese children. , 1967, Current therapeutic research, clinical and experimental.

[96]  Graham M Lord,et al.  Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. , 2002, The Journal of clinical investigation.

[97]  D. Guzick,et al.  The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. , 2008, The Journal of clinical endocrinology and metabolism.

[98]  Katherine H. Pavlovich,et al.  Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[99]  D. Simons-Morton,et al.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatrics.

[100]  G. Bray,et al.  Treatment of hypothalamic obesity with caffeine and ephedrine. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[101]  M. Nauck Liraglutide, a once-daily human GLP-1 analogue , 2008 .

[102]  E. Diamanti-Kandarakis,et al.  Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. , 2006, Fertility and sterility.

[103]  K. Fujioka,et al.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. , 1999, JAMA.

[104]  K. Yoon,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.

[105]  C. Lämmer,et al.  [Changes in carbohydrate metabolism and insulin resistance in patients with Prader-Willi Syndrome (PWS) under growth hormone therapy]. , 2007, Wiener medizinische Wochenschrift.

[106]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[107]  D. Schlundt,et al.  Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children. , 2001, Diabetes care.

[108]  S. Norgren,et al.  Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. , 2007, The Journal of clinical endocrinology and metabolism.

[109]  L. Meacham,et al.  The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. , 2002, Archives of pediatrics & adolescent medicine.

[110]  S. Heymsfield,et al.  Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. , 2005, The Journal of clinical investigation.

[111]  W. Dietz,et al.  Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. , 1992, The New England journal of medicine.

[112]  A. Astrup,et al.  Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[113]  J. Purnell,et al.  Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. , 2003, The Journal of clinical endocrinology and metabolism.

[114]  A. Belza,et al.  Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects , 2007, International Journal of Obesity.

[115]  Topiramate for weight reduction in duchenne muscular dystrophy , 2005, Muscle & nerve.

[116]  G G Enas,et al.  Fluoxetine: a randomized clinical trial in the treatment of obesity. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[117]  N. Lehmann,et al.  Effects of Growth Hormone Therapy on Cardiac Dimensions in Children and Adolescents with Prader-Willi Syndrome , 2010, Hormone Research in Paediatrics.

[118]  S. Toubro,et al.  Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[119]  William Caplan,et al.  Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. , 2007, Journal of the American Dietetic Association.

[120]  R R Wing,et al.  Ten-year outcomes of behavioral family-based treatment for childhood obesity. , 1994, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[121]  S. Murray,et al.  Multiple‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double‐Blind Study , 2010, Journal of clinical pharmacology.

[122]  J. Chanoine,et al.  Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. , 2011, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.

[123]  L. Aronne,et al.  Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial , 2010, Obesity.

[124]  Peter T Katzmarzyk,et al.  Relation of body mass index and skinfold thicknesses to cardiovascular disease risk factors in children: the Bogalusa Heart Study. , 2009, The American journal of clinical nutrition.

[125]  J. Yanovski Intensive therapies for pediatric obesity. , 2001, Pediatric clinics of North America.

[126]  A. Astrup,et al.  The Effect of Tesofensine on appetite , 2012 .

[127]  K. Flegal,et al.  Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. , 2012, JAMA.

[128]  U. Pagotto,et al.  Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome , 2006 .

[129]  Kevin W Lutz,et al.  Effectiveness of primary care interventions for weight management in children and adolescents: an updated, targeted systematic review for the USPSTF , 2010 .

[130]  R. Jorde,et al.  Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. , 1996, Diabetes & metabolism.

[131]  J. Schwartz,et al.  Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes. , 1991, Metabolism: clinical and experimental.

[132]  J. Swanson,et al.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. , 2002, Pediatrics.

[133]  S. Barlow,et al.  Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. , 2007, Pediatrics.

[134]  R. Berkowitz,et al.  Weight Loss in Obese African American and Caucasian Adolescents: Secondary Analysis of a Randomized Clinical Trial of Behavioral Therapy Plus Sibutramine , 2007, The Journal of cardiovascular nursing.

[135]  A. Starodubova,et al.  Complications of obesity in children and adolescents , 2012 .

[136]  S. Czernichow,et al.  Prevalence of overweight in 6- to 15-year-old children in central/western France from 1996 to 2006: trends toward stabilization , 2009, International Journal of Obesity.

[137]  F. Greenway,et al.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.

[138]  T. Wadden,et al.  Randomized trial of lifestyle modification and pharmacotherapy for obesity. , 2005, The New England journal of medicine.

[139]  S. Booth,et al.  Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents , 2002, Pharmacotherapy.

[140]  Rebecca S. Williamson,et al.  The National Health and Nutrition Examination Survey, 1999–2006 , 2011 .

[141]  Leila C. Kahwati,et al.  Prevention and treatment of overweight in children and adolescents. , 2004, American family physician.

[142]  M. Atabek,et al.  Use of Metformin in Obese Adolescents with Hyperinsulinemia: A 6-month, Randomized, Double-blind, Placebo-controlled Clinical Trial , 2008, Journal of pediatric endocrinology & metabolism : JPEM.

[143]  A. Prentice,et al.  Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.

[144]  V. Hubbard,et al.  Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. , 2002, Obesity research.

[145]  Jennifer L Baker,et al.  The levelling off of the obesity epidemic since the year 1999 – a review of evidence and perspectives , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[146]  J. Lindh,et al.  Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis , 2011, Journal of psychopharmacology.

[147]  D. Maahs,et al.  Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[148]  N. Rodger,et al.  Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes , 1997, International Journal of Obesity.

[149]  C. Scrimgeour,et al.  Changes in body composition and energy expenditure after six weeks' growth hormone treatment. , 1991, Archives of disease in childhood.

[150]  D. Ferraro,et al.  Topiramate in the prevention of pediatric migraine: literature review , 2008, The Journal of Headache and Pain.

[151]  M. Thorén,et al.  Growth hormone treatment improves body composition in adults with Prader–Willi syndrome , 2003, Clinical endocrinology.

[152]  M. Pfister,et al.  Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight , 2010, Diabetes, obesity & metabolism.

[153]  M. Freemark,et al.  The Effects of Metformin on Body Mass Index and Glucose Tolerance in Obese Adolescents With Fasting Hyperinsulinemia and a Family History of Type 2 Diabetes , 2001, Pediatrics.

[154]  P. Gorden,et al.  Efficacy of leptin therapy in the different forms of human lipodystrophy , 2009, Diabetologia.

[155]  L. Aronne,et al.  Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.

[156]  M. Flynn,et al.  Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with ‘best practice’ recommendations , 2006, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[157]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.

[158]  B. Ozkan,et al.  Addition of orlistat to conventional treatment in adolescents with severe obesity , 2004, European Journal of Pediatrics.

[159]  J. Swanson,et al.  Safety and tolerability of methylphenidate in preschool children with ADHD. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[160]  C. Leitão,et al.  Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[161]  Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. , 2003 .

[162]  L. Grummer-Strawn,et al.  Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study. , 2007, The American journal of clinical nutrition.

[163]  W. Coutinho,et al.  Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. , 2005, The Journal of clinical endocrinology and metabolism.

[164]  Alicia R. Desilets,et al.  Pharmacotherapeutic Options for Overweight Adolescents , 2007, The Annals of pharmacotherapy.

[165]  T. Bridger,et al.  Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. , 2006, Archives of pediatrics & adolescent medicine.

[166]  L. Kaplan,et al.  Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.

[167]  J. Zhi,et al.  The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents , 2003, Journal of the American College of Nutrition.

[168]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[169]  H. Mehnert Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[170]  B. Del-Río-Navarro,et al.  Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. , 2006, Clinical therapeutics.

[171]  Terence Dwyer,et al.  Childhood adiposity, adult adiposity, and cardiovascular risk factors. , 2011, The New England journal of medicine.

[172]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[173]  G. Medeiros-Neto,et al.  Is DL-fenfluramine a potentially helpful drug therapy in overweight adolescent subjects? , 1994, Obesity research.

[174]  S. Toubro,et al.  Weight Loss, HbA1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo‐controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical) , 2010, Obesity.

[175]  S. Heymsfield,et al.  Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. , 2002, The Journal of clinical endocrinology and metabolism.

[176]  Tanya M. Teslovich,et al.  Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index , 2010 .

[177]  V. Myllylä,et al.  Thyroid Function in Men Taking Carbamazepine, Oxcarbazepine, or Valproate for Epilepsy , 2001, Epilepsia.

[178]  Joy Hirsch,et al.  Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. , 2008, The Journal of clinical investigation.

[179]  M. Petzold,et al.  Childhood overweight and obesity prevalences levelling off in Stockholm but socioeconomic differences persist , 2008, International Journal of Obesity.

[180]  Victor M. Montori,et al.  Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion , 2008, The Journal of clinical endocrinology and metabolism.

[181]  S. Hercberg,et al.  Stabilization of overweight prevalence in French children between 2000 and 2007. , 2009, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.

[182]  A. Dulloo,et al.  Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[183]  J. Krakoff,et al.  Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children , 2011, Diabetes.

[184]  E. Ravussin,et al.  Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy , 2009, Obesity.

[185]  J. Zarzycki,et al.  [Effect of mazindol (teronac) on various hormonal indicators in children with simple obesity]. , 1982, Pediatria Polska.

[186]  D. Singh-Franco,et al.  The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis , 2011, Diabetes, obesity & metabolism.

[187]  V. Montori,et al.  Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. , 2008, The Journal of clinical endocrinology and metabolism.

[188]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[189]  S. Bloom,et al.  Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. , 2008, European journal of endocrinology.

[190]  F. Greenway The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent , 2001, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[191]  K. Parker,et al.  Long-term safety of recombinant human growth hormone in children. , 2010, The Journal of clinical endocrinology and metabolism.

[192]  J. Després,et al.  Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients , 2008, Diabetes Care.

[193]  Linda Koch Obesity: Taranabant no longer developed as an antiobesity agent , 2010, Nature Reviews Endocrinology.

[194]  J. Murray A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial , 2012 .

[195]  Jun-Sing Wang,et al.  Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. , 2011, Clinical therapeutics.

[196]  S. Schinner,et al.  Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice , 2009 .

[197]  P Kopelman,et al.  Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients , 2007, International Journal of Obesity.

[198]  M. Westerterp-Plantenga,et al.  The effectiveness of long-term supplementation of carbohydrate, chromium, fibre and caffeine on weight maintenance , 1997, International Journal of Obesity.

[199]  R. Doleček Endocrine studies with mazindol in obese patients. , 1980, Pharmatherapeutica.

[200]  D. J. Driscoll,et al.  Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[201]  R. Legro Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug? , 2008, The Journal of clinical endocrinology and metabolism.

[202]  S. Murray,et al.  Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus , 2010, Journal of clinical pharmacology.

[203]  R. Rothman,et al.  Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. , 1999, Circulation.

[204]  R. Devos,et al.  Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. , 1995, Science.

[205]  L. Hayman Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial , 2007 .

[206]  L. Kaplan Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.

[207]  J. Kennedy,et al.  The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. , 2012, The international journal of neuropsychopharmacology.

[208]  J. Yanovski,et al.  Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. , 2004, The Journal of clinical endocrinology and metabolism.

[209]  C. Cox,et al.  Long‐term Weight Control Study VI , 1992 .

[210]  M. Goldman,et al.  Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. , 2006, The Israel Medical Association journal : IMAJ.

[211]  O. Pekin,et al.  Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. , 2008, Fertility and sterility.

[212]  N. Gupta,et al.  Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial , 2010, Schizophrenia Research.

[213]  Michael Weintraub,et al.  Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. , 1992, Clinical pharmacology and therapeutics.

[214]  C. Boozer,et al.  Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial , 2002, International Journal of Obesity.

[215]  A. Astrup,et al.  Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. , 2007, American journal of physiology. Endocrinology and metabolism.

[216]  R. Berria,et al.  Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone , 2009, Diabetes Care.

[217]  P. Shekelle,et al.  Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.

[218]  P. Janicak,et al.  Topiramate plus risperidone for controlling weight gain and symptoms in preschool mania. , 2002, Journal of child and adolescent psychopharmacology.

[219]  B. Goldstein,et al.  Efficacy and safety of sitagliptin and the fixed‐dose combination of sitagliptin and metformin vs. pioglitazone in drug‐naïve patients with type 2 diabetes , 2011, International journal of clinical practice.

[220]  T. Umemura,et al.  Severe hepatic injury caused by orlistat. , 2006, The American journal of medicine.

[221]  N. Uli,et al.  Pharmacotherapy in pediatric obesity: Current agents and future directions , 2009, Reviews in Endocrine and Metabolic Disorders.

[222]  M. B. Andelman,et al.  Treatment of Obesity in Underprivileged Adolescents , 1967, Clinical pediatrics.

[223]  K. Fujioka,et al.  Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. , 2007, The Journal of clinical endocrinology and metabolism.

[224]  C. White,et al.  Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. , 2004, JAMA.

[225]  D. Allen,et al.  Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. , 2002, The Journal of clinical endocrinology and metabolism.

[226]  E. C. Stein,et al.  Long‐term weight control study IV (weeks 156 to 190) , 1992, Clinical pharmacology and therapeutics.

[227]  Arya M. Sharma,et al.  Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. , 2007, European heart journal.

[228]  P. Havel Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin , 2002, Current opinion in lipidology.

[229]  W. Klein-Schwartz,et al.  Abuse and toxicity of methylphenidate. , 2002, Current opinion in pediatrics.

[230]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[231]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[232]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[233]  F. Greenway,et al.  Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. , 2007, The Journal of clinical endocrinology and metabolism.

[234]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[235]  R. Lipp,et al.  Chlorphentermine as an Anorexigenic Agent In Adolescent Obesity , 1968, Clinical pediatrics.

[236]  D. Chlebna-Sokół,et al.  [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)]. , 1981, Przeglad lekarski.

[237]  S. Toubro,et al.  Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. , 2002, The American journal of clinical nutrition.

[238]  J. Licinio,et al.  Ten years of leptin replacement therapy , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[239]  J. Yanovski Behavior therapy and sibutramine for the treatment of adolescent obesity. , 2003, The Journal of pediatrics.

[240]  Joseph T. Glessner,et al.  Role of BMI‐Associated Loci Identified in GWAS Meta‐Analyses in the Context of Common Childhood Obesity in European Americans , 2011, Obesity.

[241]  Valeri Craigle MedWatch–The FDA Safety Information and Adverse Event-Reporting Program , 2007, Red Book (2012).

[242]  M. Nakata,et al.  Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors , 2008, Regulatory Peptides.

[243]  P. Houck,et al.  Family-Based Treatment of Severe Pediatric Obesity: Randomized, Controlled Trial , 2009, Pediatrics.

[244]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[245]  Brian E. Saelens,et al.  Recommendations for Treatment of Child and Adolescent Overweight and Obesity , 2007, Pediatrics.

[246]  Katherine H. Pavlovich,et al.  Integrative and Translational Physiology : Integrative Aspects of Energy Homeostasis and Metabolic Diseases Effects of weight loss and leptin on skeletal muscle in human subjects , 2011 .

[247]  J. Gosden,et al.  Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. , 2009, British journal of clinical pharmacology.

[248]  Adesh K. Jain,et al.  Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. , 2002, Obesity research.

[249]  Shu-chen Wu,et al.  Topiramate Monotherapy in Newly Diagnosed Epilepsy in Children and Adolescents , 2007, Journal of child neurology.

[250]  S. Norgren,et al.  Orlistat treatment in obese prepubertal children: a pilot study , 2003, Acta paediatrica.

[251]  C. Rock,et al.  Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial , 2011, Obesity.

[252]  R. Saad,et al.  Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. , 2002, The Journal of clinical endocrinology and metabolism.

[253]  N. Shapira,et al.  Topiramate for reversing atypical antipsychotic weight gain. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[254]  J. Santiago,et al.  Leptin concentrations in Prader‐Willi syndrome before and after growth hormone replacement , 2000, Clinical endocrinology.

[255]  Jebediah J. Northern,et al.  A meta-analysis of family-behavioral weight-loss treatments for children. , 2007, Clinical psychology review.

[256]  Sum Lam,et al.  Sitagliptin: A Novel Drug for the Treatment of Type 2 Diabetes , 2007, Cardiology in review.

[257]  D. Molnár,et al.  Presence of metabolic cardiovascular syndrome in obese children , 2000, European Journal of Pediatrics.

[258]  A. Mushlin,et al.  A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. , 1984, Archives of internal medicine.

[259]  T. Lobstein,et al.  Worldwide trends in childhood overweight and obesity. , 2006, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.

[260]  S. Daniels,et al.  Cardiovascular Effects of Sibutramine in the Treatment of Obese Adolescents: Results of a Randomized, Double-Blind, Placebo-Controlled Study , 2007, Pediatrics.

[261]  R. Townsend,et al.  High-fat meals reduce 24-h circulating leptin concentrations in women. , 1999, Diabetes.

[262]  R. Padwal Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. , 2009, Current opinion in investigational drugs.

[263]  R. Ness-Abramof Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2010 .

[264]  G. Bray,et al.  Current and potential drugs for treatment of obesity. , 1999, Endocrine reviews.

[265]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[266]  J. Stockman Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial , 2007 .

[267]  D. Lawlor,et al.  Obesity in children. Part 1: Epidemiology, measurement, risk factors, and screening , 2008, BMJ : British Medical Journal.

[268]  M. Jensen,et al.  Effects of growth hormone administration in human obesity. , 2003, Obesity research.

[269]  C. Summerbell,et al.  Interventions for treating obesity in children. , 2009, The Cochrane database of systematic reviews.

[270]  Rass,et al.  Phenylpropanolamine and the Risk of Hemorrhagic Stroke , 2000 .

[271]  A. Astrup,et al.  The Effect of Tesofensine on Appetite Sensations , 2012, Obesity.

[272]  G. Frost,et al.  Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[273]  A. Christopoulos,et al.  Amylin receptors: molecular composition and pharmacology. , 2004, Biochemical Society transactions.

[274]  C. Mazzoni,et al.  Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome , 2005, Journal of pediatric endocrinology & metabolism : JPEM.

[275]  C. Fox,et al.  Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study , 2012, Obesity.

[276]  B. Del-Río-Navarro,et al.  Use of sibutramine in obese hispanic adolescents , 2005, Advances in therapy.

[277]  N. Fountain A Pregnant Pause to Consider Teratogenicity of Topiramate , 2009, Epilepsy currents.

[278]  E. Waters,et al.  Interventions for treating obesity in children (a review)1 , 2007 .

[279]  D. Hill,et al.  Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance , 2009, Endocrine.

[280]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[281]  Robert V Farese,et al.  Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. , 2012, Cell metabolism.

[282]  E. Bullmore,et al.  Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs , 2011, CNS neuroscience & therapeutics.

[283]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[284]  K. Flegal,et al.  Evidence that the prevalence of childhood overweight is plateauing: data from nine countries. , 2011, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.

[285]  R. Kelishadi,et al.  A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity , 2010, World journal of pediatrics : WJP.